Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

929 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO.
Schneider EK, Reyes-Ortega F, Wilson JW, Kotsimbos T, Keating D, Li J, Velkov T. Schneider EK, et al. Among authors: wilson jw. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Dec 1;1038:57-62. doi: 10.1016/j.jchromb.2016.10.026. Epub 2016 Oct 24. J Chromatogr B Analyt Technol Biomed Life Sci. 2016. PMID: 27792891 Free PMC article.
The AWESCORE, a patient-reported outcome measure: development, feasibility, reliability, validity and responsiveness for adults with cystic fibrosis.
Button BM, Wilson LM, Burge AT, Kimmel L, Finlayson F, Williams E, Talbot A, Tierney A, King S, Holland AE, Keating D, Kotsimbos T, Wilson JW. Button BM, et al. Among authors: wilson lm, wilson jw. ERJ Open Res. 2021 Sep 20;7(3):00120-2021. doi: 10.1183/23120541.00120-2021. eCollection 2021 Jul. ERJ Open Res. 2021. PMID: 34549047 Free PMC article.
Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551 D cystic fibrosis transmembrane conductance regulator mutation: A double-blind, placebo-controlled, randomized, crossover study with open-label extension.
King SJ, Tierney AC, Edgeworth D, Keating D, Williams E, Kotsimbos T, Button BM, Wilson JW. King SJ, et al. Among authors: wilson jw. Nutrition. 2021 May;85:111124. doi: 10.1016/j.nut.2020.111124. Epub 2021 Feb 8. Nutrition. 2021. PMID: 33571868 Clinical Trial.
929 results